Literature DB >> 20359631

Mouse models of myelodysplastic syndromes.

Sarah H Beachy1, Peter D Aplan.   

Abstract

Three general approaches have been used to model myelodysplastic syndrome (MDS) in mice, including treatment with mutagens or carcinogens, xenotransplantation of human MDS cells, and genetic engineering of mouse hematopoietic cells. This article discusses the phenotypes observed in available mouse models for MDS with a concentration on a model that leads to aberrant expression of conserved homeobox genes that are important regulators of normal hematopoiesis. Using these models of MDS should allow a more complete understanding of the disease process and provide a platform for preclinical testing of therapeutic approaches. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359631      PMCID: PMC2848962          DOI: 10.1016/j.hoc.2010.02.002

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  71 in total

1.  SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival.

Authors:  Q Liu; T Sasaki; I Kozieradzki; A Wakeham; A Itie; D J Dumont; J M Penninger
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

Review 2.  Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.

Authors:  Natasa Tosić; Maja Stojiljković; Natasa Colović; Milica Colović; Sonja Pavlović
Journal:  Cancer Genet Cytogenet       Date:  2009-09

3.  Characterization of human ovarian carcinomas in a SCID mouse model.

Authors:  Y Xu; D F Silver; N P Yang; E Oflazoglu; R E Hempling; M S Piver; E A Repasky
Journal:  Gynecol Oncol       Date:  1999-02       Impact factor: 5.482

4.  Transplantation of a myelodysplastic syndrome by a long-term repopulating hematopoietic cell.

Authors:  Yang Jo Chung; Chul Won Choi; Christopher Slape; Terry Fry; Peter D Aplan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-03       Impact factor: 11.205

5.  A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

6.  EVI1 Impairs myelopoiesis by deregulation of PU.1 function.

Authors:  Leopoldo Laricchia-Robbio; Kavitha Premanand; Ciro R Rinaldi; Giuseppina Nucifora
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

7.  Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction.

Authors:  Michael L Chen; T Daniel Logan; Maryann L Hochberg; Suresh G Shelat; Xiang Yu; Gregory E Wilding; Wei Tan; Gregory C Kujoth; Tomas A Prolla; Mary A Selak; Mondira Kundu; Martin Carroll; James E Thompson
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

8.  NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.

Authors:  S Z Raza-Egilmez; S N Jani-Sait; M Grossi; M J Higgins; T B Shows; P D Aplan
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

9.  Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells.

Authors:  Jianchang Yang; Li Chai; Taylor C Fowles; Zaida Alipio; Dan Xu; Louis M Fink; David C Ward; Yupo Ma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-05       Impact factor: 11.205

10.  Identification of chromatin remodeling genes Arid4a and Arid4b as leukemia suppressor genes.

Authors:  Mei-Yi Wu; Karen W Eldin; Arthur L Beaudet
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

View more
  18 in total

1.  Brief report: Loss of p15Ink4b accelerates development of myeloid neoplasms in Nup98-HoxD13 transgenic mice.

Authors:  Rita Humeniuk; Richard Koller; Juraj Bies; Peter Aplan; Linda Wolff
Journal:  Stem Cells       Date:  2014-05       Impact factor: 6.277

2.  Loss of the tumor suppressor BAP1 causes myeloid transformation.

Authors:  Anwesha Dey; Dhaya Seshasayee; Rajkumar Noubade; Dorothy M French; Jinfeng Liu; Mira S Chaurushiya; Donald S Kirkpatrick; Victoria C Pham; Jennie R Lill; Corey E Bakalarski; Jiansheng Wu; Lilian Phu; Paula Katavolos; Lindsay M LaFave; Omar Abdel-Wahab; Zora Modrusan; Somasekar Seshagiri; Ken Dong; Zhonghua Lin; Mercedesz Balazs; Rowena Suriben; Kim Newton; Sarah Hymowitz; Guillermo Garcia-Manero; Flavius Martin; Ross L Levine; Vishva M Dixit
Journal:  Science       Date:  2012-08-09       Impact factor: 47.728

Review 3.  Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research.

Authors:  Ting Zhou; Marsha C Kinney; Linda M Scott; Sandra S Zinkel; Vivienne I Rebel
Journal:  Blood       Date:  2015-06-15       Impact factor: 22.113

4.  Mice heterozygous for CREB binding protein are hypersensitive to γ-radiation and invariably develop myelodysplastic/myeloproliferative neoplasm.

Authors:  Stephanie N Zimmer; Madeleine E Lemieux; Bijal P Karia; Claudia Day; Ting Zhou; Qing Zhou; Andrew L Kung; Uthra Suresh; Yidong Chen; Marsha C Kinney; Alexander J R Bishop; Vivienne I Rebel
Journal:  Exp Hematol       Date:  2011-12-20       Impact factor: 3.084

Review 5.  A research review of experimental animal models with myelodysplastic syndrome.

Authors:  Gen-Wang Chen; Mei-Na Chen; Lei Liu; Yu-Yu Zheng; Jin-Peng Wang; Si-Si Gong; Rong-Fu Huang; Chun-Mei Fan; Yue-Zu Chen
Journal:  Clin Transl Oncol       Date:  2022-09-06       Impact factor: 3.340

6.  Growth factor independence 1 (Gfi1) regulates cell-fate decision of a bipotential granulocytic-monocytic precursor defined by expression of Gfi1 and CD48.

Authors:  Lothar Vassen; Ulrich Dührsen; Christian Kosan; Hui Zeng; Tarik Möröy
Journal:  Am J Blood Res       Date:  2012-11-25

7.  Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation.

Authors:  Esther A Obeng; Ryan J Chappell; Michael Seiler; Michelle C Chen; Dean R Campagna; Paul J Schmidt; Rebekka K Schneider; Allegra M Lord; Lili Wang; Rutendo G Gambe; Marie E McConkey; Abdullah M Ali; Azra Raza; Lihua Yu; Silvia Buonamici; Peter G Smith; Ann Mullally; Catherine J Wu; Mark D Fleming; Benjamin L Ebert
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 8.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

9.  Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Authors:  Tushar D Bhagat; Si Chen; Matthias Bartenstein; A Trevor Barlowe; Dagny Von Ahrens; Gaurav S Choudhary; Patrick Tivnan; Elianna Amin; A Mario Marcondes; Mathijs A Sanders; Remco M Hoogenboezem; Suman Kambhampati; Nandini Ramachandra; Iaonnis Mantzaris; Vineeth Sukrithan; Remi Laurence; Robert Lopez; Prafullla Bhagat; Orsi Giricz; Davendra Sohal; Amittha Wickrema; Cecilia Yeung; Kira Gritsman; Peter Aplan; Konrad Hochedlinger; Yiting Yu; Kith Pradhan; Jinghang Zhang; John M Greally; Siddhartha Mukherjee; Andrea Pellagatti; Jacqueline Boultwood; Britta Will; Ulrich Steidl; Marc H G P Raaijmakers; H Joachim Deeg; Michael G Kharas; Amit Verma
Journal:  Cancer Res       Date:  2017-07-06       Impact factor: 13.312

10.  Novel spontaneous myelodysplastic syndrome mouse model.

Authors:  Weisha Li; Lin Cao; Mengyuan Li; Xingjiu Yang; Wenlong Zhang; Zhiqi Song; Xinpei Wang; Lingyan Zhang; Grant Morahan; Chuan Qin; Ran Gao
Journal:  Animal Model Exp Med       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.